Discussion
The main diagnostic features of KMS are giant hemangioma and decreased platelet count. Giant cutaneous hemangiomas are easy to diagnose on physical examination. Visceral hemangiomas are easily missed, and patients may present with large ecchymoses. According to the cases in this research, it illustrates that KMS should be considered in children with unexplained thrombocytopenia and coagulation disorders. Routine blood testing showed varying degrees of low hemoglobin concentration, low plasma fibrinogen level, and prolonged prothrombin time. B-mode ultrasonography, CT, and MRI showed the size, appearance, and layers of hemangiomas, as well as their relationships with peripheral vessels, and distinguished hemangiomas from vascular malformations.
KMS is associated with Kaposi haemangioendothelioma(KHE) in over 90% of cases according to the research findings recently, and uncommonly with infantile and congenital haemangioma. The MRI findings of KHE have some characters. It presents as an enhancing, ill-defined, soft-tissue mass that is hypointense or isointense on T1 weighted images and hyperintense on T2 weighted images compared with muscle. Prominent vascular channels, presenting as flow voids in the tumour or as linear enhancing channels adjacent to the tumour, are usually noted [
2]. However, these findings are not specific for KHE. KHE can’t be confirmed by MRI only. The identification of hemangioma type rely mainly on pathologic examination, but KMS is associated with coagulation dysfunction, which is a contraindication of pathological biopsy. So our patients accepted B-mode ultrasonography, color Doppler flow imaging, or computed tomography (CT) because of the cheaper costs. Only one patient accepted MRI.
There are currently no consensus guidelines for the treatment of KMS. Some studies have reported good therapeutic effects with comprehensive sequential therapy, including steroid therapy, interferon, arterial embolization, vincristine, radiotherapy, and surgery [
3‐
5]. There are no specific guidelines for diagnosis and treatment during the neonatal period.
In infants, glucocorticoid therapy is considered to be a good choice for initial drug treatment, because it can inhibit fibrinolysis and thrombosis, stimulate hematopoiesis in the bone marrow to increase release of platelets into the bloodstream, decrease the level of anti-platelet antibodies, and increase platelet count. However, it is only effective in 30% to 50% of patients with KMS [
6,
7]. Glucocorticoid therapy may be administered orally, intravenously, or locally; and commonly starts to show effectiveness at 1–2 weeks after the onset of treatment [
8]. Our patients were treated with intravenous dexamethasone 1 mg/kg/day, and the platelet count started to increase after 3–8 days. In this study, steroid therapy was effective in 35.3% of patients, but the relapse rate was high (50%), resulting in an eventual effectiveness rate of only 17.6%. A more effective therapeutic approach is therefore necessary.
In patients who responded poorly to steroid therapy, arterial embolization was performed with bleomycin A5 (8–12 mg/m
2), iodinated oil (2 mL), and dexamethasone (2 mg). Arterial embolization has been used to treat vascular tumors for many years [
9,
10], and is useful for controlling symptoms and promoting regression of hemangiomas. However, neonates have tiny vessels, and do not tolerate such intervention well. There have been a few previous reports of treatment by arterial embolization in neonates with KMS in China, especially in patients with coagulation disorders. The dose of contrast agent needed, risk associated with general anesthesia, and difficulty in catheter placement limit the usefulness of this treatment in neonates. In the present study, arterial embolization was effective in 64.3% of patients. A previous study of arterial embolization using bleomycin A5 found that partial embolization significantly improved coagulation function and decreased hemangioma blood flow, and relieved symptoms [
11]. Another study found that local injection of urea destroyed the vascular endothelial cell matrix, suppressed endothelial cell growth, promoted endothelial cell atrophy, caused fibrosis of local tissue, hardened the tumor tissue, and caused thrombosis in the vascular lumen of the tumor body [
12]. Local injection of urea has been used to successfully treat hemangiomas and vascular malformations, and may be useful for the treatment of neonatal KMS [
12]. Arterial embolization in neonates is difficult and carries some risks, but can improve the patient’s condition if intravenous drug therapy has not controlled the hemangioma.
Intravenous vincristine has been used for the treatment of KMS, and can be used as a first-line drug in the treatment of Kaposiform hemangioendothelioma combined with KMS [
13,
14]. An American multicenter study found that vincristine therapy was useful in patients who were resistant to steroid and interferon therapy [
13,
15]. Vincristine, actinomycin, and cyclophosphamide can induce tumor regression and normalization of coagulation parameters [
16]. Although vincristine is neurotoxic, it can help to alleviate symptoms in patients with KMS. In this study, vincristine was administered to five patients who responded poorly to steroid therapy and arterial embolization, and was effective in 80% of these patients. No adverse effects related to chemotherapy were observed. These results indicate that vincristine can be used to treat neonatal KMS. However, this study only had a small number of subjects, and a larger sample is needed to confirm the effectiveness of vincristine therapy. Haisley-Royster et al. [
13] reported that platelet counts in patients with KMS increased to normal values after 5 weeks of vincristine therapy. Vincristine therapy cannot avoid hemangioma relapse, but has been reported to result in prolonged reduction in hemangioma growth [
11], which is consistent with the findings of this study.
It is worth noting that platelet transfusion is suitable for increasing the platelet count urgently or preoperatively, but it cannot be used routinely, because the hemangioma will consume the platelets [
5,
17,
18]. Moreover, platelet transfusion will promote an increase in hemangioma size by inducing blood coagulation [
5,
17,
18]. Excessive platelet transfusion has been reported to aggravate KMS [
5,
17,
18]. In this study, patients received apheresis platelet transfusions if their platelet count was <20 × 10
9/L, which allowed us to perform arterial embolization. Transfusion therefore did not aggravate their condition.
Systemic interferon therapy has been used in patients who were resistant to steroid therapy, with good results [
4,
18]. However, the effectiveness of interferon therapy is variable. Interferon therapy can be considered as a second-line drug treatment that is effective in 50% to 60% of patients, but it only has weak inhibitory effects on endothelial cell and vascular growth, and continuous treatment is needed [
19]. Continuous interferon therapy may result in increased transaminase levels, decreased platelet count, and decreased leukocyte count [
20]. A meta-analysis by Michaud et al. [
8] found that interferon therapy could cause spastic diplegia and dyskinesia in infants. They recommended that interferon therapy should not be used in patients aged less than 1 year, except when other treatment methods are ineffective and the patient’s condition is life-threatening [
8].
Leong et al. [
21] reported two neonates with KMS who received radiotherapy after full-dose steroid therapy and α-interferon therapy were ineffective, resulting in a rapid increase in platelet count. The hemangioma gradually regressed over 3 years in one patient, and fully regressed within 2 months in the other patient. No adverse effects associated with radiotherapy were detected during the follow-up periods of 8 and 5 years, respectively, suggesting that radiotherapy may be a safe and effective treatment for KMS. However, another study reported that radiotherapy for hemangioma may increase the frequency of secondary tumors [
22]. The safety and effectiveness of radiotherapy for the treatment of KMS should be evaluated in further clinical studies with follow-up over a few decades.
Competing interests
No benefits in any form have been received or will be received from any commercial party related directly or indirectly to the subject of this article.